Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.82 USD
Change Today -0.45 / -2.77%
Volume 960.1K
ADXS On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Key Developments

Advaxis, Inc. Appoints Shelonitda S. Rose as Vice President, Clinical Development

Advaxis, Inc. announced that it has appointed Shelonitda S. Rose, M.D., as Vice President, Clinical Development. Dr. Rose brings to Advaxis more than 15 years of experience in medical oncology and hematology clinical research. In her role as Vice President, Clinical Development, Dr. Rose will report to Advaxis's Executive Vice President, Chief Medical Officer, David J. Mauro, MD, Ph.D., and will oversee clinical development programs for the Company's Lm Technology™ platform. Most recently, Dr. Rose served as Director, Oncology Clinical Research for Merck & Co., Inc.

Advaxis, Inc.(NasdaqCM:ADXS) added to Russell 2000 Index

Advaxis, Inc. will be added to Russell 2000 Index

Advaxis, Inc.(NasdaqCM:ADXS) added to Russell 3000 Index

Advaxis, Inc. will be added to the Russell 3000 Index.

Advaxis, Inc. - Special Call

To review recent accomplishments and key near-term milestones of the company

Advaxis, Inc. Submits Special Protocol Assessment Request to the U.S. Food and Drug Administration to Initiate Detailed Design Discussions for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer

Advaxis, Inc. announced the company has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) to initiate detailed design discussions for a Phase 3 clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer (HRLACC). The Phase 3 trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation, Inc. and to be led by principal investigator Thomas Herzog, M.D., Professor of Obstetrics & Gynecology and Clinical Director at the University of Cincinnati Cancer Institute, Cincinnati, Ohio. The SPA request includes specific questions from Advaxis to facilitate a meaningful dialog with the FDA on the proposed study design. Following receipt, the FDA will determine the appropriateness of the SPA request and may take up to 45 calendar days to provide comments to Advaxis. The nature and extent of comments received will determine the need for additional rounds of review and/or a formal meeting. The FDA's assessment of the SPA request, and all related valuable feedback, will aid to inform the development of ADXS-HPV in locally advanced cervical cancer. The proposed Phase 3 clinical trial (AIM2CERV) is designed as an adequate and well-controlled double-blind, placebo-controlled multinational study of ADXS-HPV (ADXS11-001) administered in the adjuvant setting following concurrent chemoradiation given with curative intent in patients with HRLACC for whom recurrence has not yet occurred. Advaxis plans to initiate the Phase 3 trial by the end of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $15.82 USD -0.45

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $6.18 USD -0.06
Eurocine Vaccines AB kr2.08 SEK -0.16
Genocea Biosciences Inc $12.82 USD -1.09
GenVec Inc $2.31 USD -0.0647
View Industry Companies

Industry Analysis


Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at